PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
06 Septembre 2023 - 2:00PM
PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the
Company), a clinical-stage immunotherapy company developing a
growing pipeline of targeted cancer immunotherapies and infectious
disease vaccines based on the Company’s proprietary T cell
activating platforms, today announced that data from preclinical
studies in ferrets of PDS0202, the company’s universal influenza
vaccine utilizing proprietary COBRA (computationally optimized
broadly reactive antigen) hemagglutinin (HA) flu proteins, will be
featured in an oral lecture at the European Scientific Working
Group on Influenza (ESWI) Conference. ESWI is being held September
17-20, 2023, in Valencia, Spain.
Abstract Title: Influenza
pre-immune ferrets vaccinated with computationally optimized
recombinant HA proteins generate sero-protective antibody responses
against H1N1 and H3N2 viruses from the last decade.
Presenting Author: James Allen, PhD, Cleveland
Clinic, United States of America Session Title:
Future vaccination strategies SCS09Lecture:
Tuesday 19 September; Time 14:10-15:45 (CET)
About PDS Biotechnology PDS
Biotech is a clinical-stage immunotherapy company developing a
growing pipeline of targeted cancer and infectious disease
immunotherapies based on our proprietary Versamune®, Versamune®
plus PDS0301, and Infectimune® T cell-activating platforms. We
believe our targeted immunotherapies have the potential to overcome
the limitations of current immunotherapy approaches through the
activation of the right type, quantity and potency of T cells. To
date, our lead Versamune® clinical candidate, PDS0101, has
demonstrated the ability to reduce and shrink tumors and stabilize
disease in combination with approved and investigational
therapeutics in patients with a broad range of HPV16-associated
cancers in multiple Phase 2 clinical trials and will be advancing
into a Phase 3 clinical trial in combination with KEYTRUDA® for the
treatment of recurrent/metastatic HPV16-positive head and neck
cancer in 2023. Our Infectimune® based vaccines have also
demonstrated the potential to induce not only robust and durable
neutralizing antibody responses, but also powerful T cell
responses, including long-lasting memory T cell responses in
pre-clinical studies to date. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
About Infectimune®Infectimune®
is a novel investigational immune activating platform that
generates broad and robust antibody and T cell responses that
provide durable protection against infectious disease. Infectimune®
based vaccines are given by intramuscular injection and generate
robust and durable protection against infectious agents in
preclinical studies. Infectimune® based vaccines have demonstrated
safety in preclinical studies and appear to provide more robust and
longer-lasting protection against infectious disease.
Forward Looking Statements This
communication contains forward-looking statements (including within
the meaning of Section 21E of the United States Securities Exchange
Act of 1934, as amended, and Section 27A of the United States
Securities Act of 1933, as amended) concerning PDS Biotechnology
Corporation (the “Company”) and other matters. These statements may
discuss goals, intentions and expectations as to future plans,
trends, events, results of operations or financial condition, or
otherwise, based on current beliefs of the Company’s management, as
well as assumptions made by, and information currently available
to, management. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer
to future events or conditions, and include words such as “may,”
“will,” “should,” “would,” “expect,” “anticipate,” “plan,”
“likely,” “believe,” “estimate,” “project,” “intend,” “forecast,”
“guidance”, “outlook” and other similar expressions among others.
Forward-looking statements are based on current beliefs and
assumptions that are subject to risks and uncertainties and are not
guarantees of future performance. Actual results could differ
materially from those contained in any forward-looking statement as
a result of various factors, including, without limitation: the
Company’s ability to protect its intellectual property rights; the
Company’s anticipated capital requirements, including the Company’s
anticipated cash runway and the Company’s current expectations
regarding its plans for future equity financings; the Company’s
dependence on additional financing to fund its operations and
complete the development and commercialization of its product
candidates, and the risks that raising such additional capital may
restrict the Company’s operations or require the Company to
relinquish rights to the Company’s technologies or product
candidates; the Company’s limited operating history in the
Company’s current line of business, which makes it difficult to
evaluate the Company’s prospects, the Company’s business plan or
the likelihood of the Company’s successful implementation of such
business plan; the timing for the Company or its partners to
initiate the planned clinical trials for PDS0101, PDS0203 and other
Versamune® and Infectimune® based product candidates; the future
success of such trials; the successful implementation of the
Company’s research and development programs and collaborations,
including any collaboration studies concerning PDS0101, PDS0203 and
other Versamune® and Infectimune® based product candidates and the
Company’s interpretation of the results and findings of such
programs and collaborations and whether such results are sufficient
to support the future success of the Company’s product candidates;
the success, timing and cost of the Company’s ongoing clinical
trials and anticipated clinical trials for the Company’s current
product candidates, including statements regarding the timing of
initiation, pace of enrollment and completion of the trials
(including the Company’s ability to fully fund its disclosed
clinical trials, which assumes no material changes to the Company’s
currently projected expenses), futility analyses, presentations at
conferences and data reported in an abstract, and receipt of
interim or preliminary results (including, without limitation, any
preclinical results or data), which are not necessarily indicative
of the final results of the Company’s ongoing clinical trials; any
Company statements about its understanding of product candidates
mechanisms of action and interpretation of preclinical and early
clinical results from its clinical development programs and any
collaboration studies; and other factors, including legislative,
regulatory, political and economic developments not within the
Company’s control. The foregoing review of important factors that
could cause actual events to differ from expectations should not be
construed as exhaustive and should be read in conjunction with
statements that are included herein and elsewhere, including the
other risks, uncertainties, and other factors described under “Risk
Factors,” “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” and elsewhere in the documents
we file with the U.S. Securities and Exchange Commission. The
forward-looking statements are made only as of the date of this
press release and, except as required by applicable law, the
Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking
statements, whether as a result of new information, future events
or otherwise.
Versamune® and Infectimune® are registered
trademarks of PDS Biotechnology. KEYTRUDA® is a registered
trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck &
Co., Inc., Rahway, N.J., USA.
Investor Contacts: Deanne
Randolph PDS Biotech Phone: +1 (908) 517-3613 Email:
drandolph@pdsbiotech.com
Rich Cockrell CG Capital Phone: +1 (404)
736-3838 Email: pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
PDS Biotechnology (NASDAQ:PDSB)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024